Fig. 1From: Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case seriesRepresentative computed tomography (CT) and positron emission tomography (PET)/CT images from a 67-year-old man with advanced Merkel cell carcinoma. He experienced progressive disease after receiving pembrolizumab (two upper left panels), then an immune-related partial response to ipilimumab + nivolumab lasting 30 weeks (four upper right panels). Re-induction ipilimumab + nivolumab administered at the time of disease progression was ineffective in regaining disease control (two lower left panels). However, administration of avelumab and radiotherapy to a right iliac metastasis resulted in a partial response (RECIST v1.1) at 8 weeks. PR lasted 12 monthsBack to article page